Form 4: MariMed Inc. Insider Transactions: Jon R. Levine
Insider Transaction Report
MariMed Inc. reports insider transactions by Director and President/CEO Jon R. Levine, detailing RSU vesting and share withholding for tax purposes.
Summary
- Jon R. Levine, Director and President/CEO of MariMed Inc., reported transactions on May 29, 2026.
- 46,875 Restricted Stock Units (RSUs) were acquired, converting to common stock.
- 16,243 shares of common stock were withheld by the Issuer to cover tax obligations related to RSU vesting.
- Following these transactions, Levine beneficially owns 21,354,861 shares directly and 6,684,640 shares indirectly through the Jon Levine Family Trust.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard equity compensation and tax withholding procedures for an executive, rather than a significant strategic or financial event.
Positives
- Vesting of RSUs indicates continued incentive alignment for key executive leadership.
- The company is managing tax withholding obligations efficiently in connection with equity awards.
Negatives
- Withholding of shares for tax purposes reduces the net number of shares received by the executive, though this is a standard practice.
Future Outlook
The filing indicates that remaining RSUs granted on November 29, 2024, will vest in three equal installments on November 29, 2026, May 29, 2027, and November 29, 2027.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, providing transparency into insider trading activities. This filing specifically details equity compensation events for a key executive at MariMed Inc., a company operating in the cannabis industry, which often utilizes equity-based compensation to attract and retain talent.
Stakeholder Impact
- Shareholders gain insight into executive compensation and potential future share dilution from RSU vesting.
- Employees may view executive equity awards as a sign of company growth and commitment to its leadership.
- Creditors are not directly impacted by this type of filing.
Next Steps
- Vesting of remaining RSUs on scheduled dates: November 29, 2026, May 29, 2027, and November 29, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/29/2026 | Earliest transaction date reported for Form 4 filing. |
| 11/29/2024 | Grant date for remaining RSUs that will vest in installments. |
| 11/29/2026 | First installment vesting date for remaining RSUs. |
| 05/29/2027 | Second installment vesting date for remaining RSUs. |
| 11/29/2027 | Final installment vesting date for remaining RSUs. |
| 06/01/2026 | Date of signature on the Form 4 filing. |
Keywords
MariMed Inc., MRMD, Form 4, Insider Transaction, Jon R. Levine, Restricted Stock Units, RSU Vesting, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.